MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-derived peptide. Lee and colleagues' 2015 report identified its coding sequence within the mitochondrial 12S rRNA gene. Mitochondrial genetic origin does not mean the peptide is necessarily synthesized inside mitochondria. Lee and colleagues, 2015

It is studied as a signal connecting metabolism with cellular stress responses. In cell experiments, MOTS-c entered the nucleus during metabolic stress and influenced gene regulation, highlighting a form of communication between mitochondrial and nuclear genomes. Kim and colleagues, 2018

The term exercise mimetic describes experimental overlap with exercise-related signaling. The evidence includes mouse treatment studies and human measurements of the body's own peptide; these answer different questions. Reynolds and colleagues, 2021

Several experimental findings explain interest in MOTS-c:

AMPK signaling: Cell experiments link MOTS-c to AMPK, a regulator of cellular energy balance. This is one reason researchers are interested in its metabolic effects. Lee and colleagues, 2015

Folate and purine metabolism: The discovery study connected altered folate-cycle and purine metabolism with accumulation of AICAR, an AMPK-activating intermediate. Lee and colleagues, 2015

Nuclear signaling: A 2018 study reported AMPK-dependent movement into the nucleus during metabolic stress and interactions with NRF2-associated antioxidant-response gene regulation in cells. Kim and colleagues, 2018

Insulin sensitivity: The 2015 experiments found protection against age-related and high-fat-diet-associated insulin resistance in mice, supporting further research on metabolic disease. Lee and colleagues, 2015

Physical capacity: A 2021 study found improved performance in treated mice across age groups. Its human exercise component measured endogenous MOTS-c rather than administering it. Reynolds and colleagues, 2021

Metabolic regulation — animal evidence: The original mouse experiments also found reduced high-fat-diet-associated obesity. These are promising preclinical findings; the human intervention evidence is considered separately below. Lee and colleagues, 2015

Exercise and healthspan — animal evidence: The 2021 paper reported favorable mouse physical-function measures, including with late-life treatment. The overall survival-curve comparison was not statistically significant (P=0.23), so these results should not be summarized as proven lifespan extension. Reynolds and colleagues, 2021

Aging — human observational evidence: A 2020 study of healthy men found lower circulating MOTS-c but higher skeletal-muscle levels in older groups. Blood and muscle samples in the older groups came from different participants. Plasma levels were not significantly associated with HOMA-IR in that cohort; these observations do not establish that peptide replacement treats aging. D’Souza and colleagues, 2020

Human intervention research: As checked October 2, 2026, the sponsor-submitted NCT07505745 record lists a native MOTS-c study as recruiting, with 120 estimated participants and no posted results. Separately, NCT03998514 studied CB4211, a modified analog, and lists completion with 88 actual participants but no posted results. CohBar's 2021 announcement reported favorable liver-enzyme and glucose findings in a 20-person, four-week CB4211 cohort; liver fat decreased in both treatment and placebo groups. These are sponsor-reported analog findings, not proof of native MOTS-c efficacy. MOTS-c trial registry CB4211 trial registry CohBar’s 2021 results announcement

Bone research — animal and cell evidence: A 2016 ovariectomized-mouse study found reduced bone loss and inhibition of osteoclast differentiation. A separate 2018 study reported osteogenic differentiation in cultured rat bone-marrow cells. Neither establishes MOTS-c as a treatment for human osteoporosis. 2016 mouse bone-loss study Hu and Chen, 2018

Human dosing evidence: The cited evidence does not establish a general-use native MOTS-c dose. Animal exposures and CB4211 analog doses cannot be used interchangeably with native MOTS-c dosing in people.

Trial regimens: NCT07505745 describes fixed-dose daily subcutaneous administration for 12 weeks, but its intervention entry does not supply a milligram amount. A registered research schedule is not a validated self-use protocol. MOTS-c trial registry

Cycling and timing: The sources above do not validate a universal on/off cycle, morning schedule or exercise-linked dosing routine. Such suggestions should be identified as informal practices, not clinical instructions.

Preparation and storage: Diluent, concentration and usable life depend on the actual formulation and its validated handling instructions. A generic bacteriostatic-water recipe or two-to-three-week refrigerated shelf life is not established by the studies cited here.

Endogenous presence is not a safety test: A peptide occurring naturally in the body does not establish the safety of administering it at a different exposure or in a particular formulation.

Anecdotal reports: Informal reports about energy, fatigue, sleep or injection-site symptoms can help identify questions for research, but they do not establish frequency, causation or a reliable tolerability profile.

Early analog safety findings: CohBar reported no serious adverse events with CB4211 in its early trial, with transient, generally mild-to-moderate injection-site reactions in the four-week cohort. This is encouraging early information about that analog, not a long-term safety finding for native MOTS-c. CohBar’s 2021 results announcement

What remains unresolved: The evidence cited here does not establish native MOTS-c's long-term safety, interaction profile or safety in people with active cancer. Cellular mechanisms alone cannot prove either clinical harm or protection in those settings.